Randomized, Phase III Study of Early Intervention With Venetoclax and Obinutuzumab Versus Delayed Therapy With Venetoclax and Obinutuzumab in Newly Diagnosed Asymptomatic High-Risk Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): EVOLVE CLL/SLL Study
For more information about the trial above please contact the study team:
Principal Investigator, Brian Hess, at firstname.lastname@example.org.
Study Coordinator, Sarah Britton, at email@example.com, or please call +1 843-792-8856.
Trial opened at the following institutions: Medical University of South Carolina